Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7292-7300

  Shalom Feuerstein, Ruby ^a   Cooks, Tomer ^a   Raz, Avraham ^b   Kloog, Yoel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; FARNESYLTHIOSALICYLIC ACID; GALECTIN 3; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; RAS PROTEIN;

ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; CARCINOMA CELL; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; WILD TYPE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; GALECTIN 3; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; PROTEIN ISOFORMS; RAS PROTEINS;

EID: 23844534708     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0775     Document Type: Article

References (27)

1. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002;277:6852-7.
2. Yu F, Finley RL Jr, Raz A, Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 2002;277:15819-27.
3. Kim HR, Lin HM, Biliran H. Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999;59:4148-54.
4. Elad-Sfadia G. Haklai R, Balan E, Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 2004;279:34922-30.
5. Downward J. Role of receptor tyrosine kinases in G-protein-coupled receptor regulation of Ras: transactivation or parallel pathways? Biochem J 2003;376:e9-10.
6. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999-9006.
7. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998;8:49-54.
8. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 2000;10:147-54.
9. McFall A, Ulku A, Lambert QT, Kusa A, Rogers-Graham K, Der CJ. Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol Cell Biol 2001;21:5488-99.
10. Shalom-Feuerstein R, Lindenboim L, Stein R, Cox AD, Kloog Y. Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor. Cell Death Differ 2004;11:244-7.
11. Niv H, Gutman O, Henis YI, Kloog Y. Membrane interactions of a constitutively active GFP-Ki-Ras 4B and their role in signaling. Evidence from lateral mobility studies. J Biol Chem 1999;274:1606-13.
12. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001;20:7486-93.
13. Pardo OE, Arcaro A, Salerno G, Raguz S, Downward J, Seckl MJ. Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem 2002;277: 12040-6.
14. Hall A. The cellular functions of small GTP-binding proteins. Science 1990;249:635-40.
15. Wolfman A, Ras isoform-specific signaling: location, location, location. Sci STKE 2001;2001:PE2.
16. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J 2004;19:543-9.
17. Takenaka Y, Fukumori T, Yoshii T, et al. Nuclear export of phosphorylated galectin-3 regulates its anti-apoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004;24:4395-406.
18. Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y. The Ras inhibitor S-trans.transfarnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 2002;8: 555-65.
19. Halaschek-Wiener J, Kloog Y, Wacheck V, Jansen B. Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo. J Invest Dermatol 2003;120:109-15.
20. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002;1572:263-73.
21. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, Raz A. Galectin-3. a novel binding partner of -catenin. Cancer Res 2004;64:6363-7.
22. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
23. Hancock JF. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 2003;4: 373-84.
24. Jones MK, Jackson JH. Ras-GRF activates Ha-Ras. but not N-Ras or K-Ras 4B. protein in vivo. J Biol Chem 1998;273:1782-7.
25. Bivona TG, Philips MR. Ras pathway signaling on endomembranes. Curr Opin Cell Biol 2003;15:136-42.
26. Chiu VK, Bivona T, Hach A, et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol 2002;4:343-50.
27. Yan J, Roy S, Apolloni A, Lane A, Hancock JF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 1998;273: 24052-6.